PharmaBoardroom

The following is an overview from Accestra Consulting* of Part 2 of China’s Center for Drug Evaluation (CDE)’s 2020 reporting, including an…

The latest reporting on China biopharma dealmaking from MSQ Ventures, including the Top 10 biotech in-licensing deals in H1 2021, the Top 5…

The latest news from Chinese pharma and biotech, including news that state-owned Sinopharm is now developing its own mRNA vaccine; an update on Hong…

Song Ruilin, chairman of the China Pharmaceutical Innovation and Research Development Association (PhIRDA), picks out the key learnings from recent…

The following is an overview from Accestra Consulting* of Part 1 of China’s Center for Drug Evaluation (CDE)’s 2020 reporting, including data on…

Key legal info on biosimilars & biologics in China. Prepared in association with Fangda Partners, one of China’s most prestigious and…

Want to know more about localization in China? Prepared in association with Fangda Partners, one of China’s most prestigious and well-regarded law…

An intro to the legal situation for orphan drugs and rare diseases in China. Prepared in association with Fangda Partners, one of China’s most…

Cannabinoid drugs, medicinal cannabis & opioid drugs in India - a comprehensive legal overview. Prepared in association with Fangda Partners, one…

The key facts about regulatory reforms in Chinese pharma. Prepared in association with Fangda Partners, one of China’s most prestigious and…

An outline of the legal situation around patents and trademarks for pharmaceuticals in China. Prepared in association with Fangda Partners, one of…

A comprehensive guide to the legal implications around product liability in China. Prepared in association with Fangda Partners, one of China’s…